Inside the KLOW Stack: The Four Peptides

Before the arms

The KLOW stack is four chemically distinct research peptides sharing one vial. Inside the KLOW stack — traced by mechanism — the picture is four largely non-overlapping signaling nodes in the tissue-repair cascade, each studied separately, none tested in combination. This page traces each arm through its own published mechanism, attributing every claim to its source component, and names the place where the combination evidence would sit as the unresolved gap it is.

KPV — the anti-inflammatory current

KPV (Lys-Pro-Val, MW 342.44 Da, CAS 67727-97-3) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone). Three amino acids — lysine, proline, valine — in sequence. Small enough to be taken up by PepT1, the di/tripeptide transporter that pulls small peptides across the gut epithelium; KPV's PepT1 substrate affinity has been measured at a Km of approximately 160 μM ^[3].

The mechanism in inflamed tissue: KPV is transported via PepT1 into intestinal epithelial cells and into activated macrophages, which upregulate PepT1 in inflammatory states. Inside the cell, nanomolar KPV blocks the nuclear import of NF-κB p65/RelA — the transcription factor that drives expression of the major pro-inflammatory cytokines TNF-α, IL-6, IL-1β and IL-8. It also suppresses the MAP-kinase cascade (ERK/p38) that amplifies cytokine output. The result in cultured human intestinal epithelial cells is a measurable reduction in inflammatory cytokine secretion at concentrations as low as 10 nM ^[3].

In C57BL/6 mouse DSS- and TNBS-induced colitis, oral KPV reduced colitis severity — evidence that the mechanism translates from cell culture to inflamed tissue in vivo ^[3]. The KPV-loaded mucoadhesive hydrogel work extended this to a wound context, demonstrating combined anti-inflammatory and pro-healing effects at the application site ^[12].

KPV has not reached clinical approval. Its human data are confined to delivery feasibility studies and an IBD-research program lineage; no controlled human monotherapy trial has been completed.

GHK-Cu — the matrix and copper current

GHK-Cu (Gly-His-Lys copper(II) complex, Copper Tripeptide-1, MW 402.92 Da, CAS 89030-95-5) is the mass-dominant component of the blend at ~62.5% by mass. It is the oldest of the four in the research record, first isolated from human plasma by Loren Pickart in 1973. Its plasma concentration is not static: roughly 200 ng/mL in a 20-year-old, declining to about 80 ng/mL by age 60 — a trajectory that has made GHK-Cu interesting in the anti-aging skin literature ^[4].

At low-nanomolar concentrations GHK-Cu acts as a broad transcriptomic modulator. The 2018 Connectivity Map analysis found it shifting expression of approximately 31.2% of assayed human genes at a ≥50% change threshold in cultured fibroblasts, with the strongest upregulated signals on extracellular-matrix remodeling, ubiquitin-proteasome protein quality-control, DNA-repair and antioxidant gene sets ^[5]. The dominant direction is pro-repair: procollagen-I and procollagen-IV induction, dermatan sulfate and decorin stimulation, antioxidant-enzyme upregulation.

GHK-Cu also supplies copper for lysyl oxidase — the copper-dependent enzyme that crosslinks collagen and elastin to form the load-bearing matrix scaffold. This places GHK-Cu at the intersection of transcriptional signaling and direct enzymatic cofactor supply.

Proteolysis of SPARC (osteonectin) releases copper-binding peptides including GHK and the more potent KGHK that stimulate angiogenesis in endothelial cultures and in vivo, linking GHK peptides to endogenous angiogenesis regulation beyond their topical record ^[9].

Human data for GHK-Cu are robust in the topical/cosmetic domain: the comparative trial showed improved collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented improvements in skin texture, fine-line depth and clarity ^[4]. No systemic human trial has been conducted.

BPC-157 — the angiogenic current

BPC-157 (pentadecapeptide GEPPPGKPADDAGLV, MW 1419.53 Da, CAS 137525-51-0) is the largest molecule in the blend and, by depth of rodent literature, the best studied of the four. Originally developed as PL 14736 for inflammatory bowel disease, it has accumulated an extensive repair literature spanning tendon, ligament, muscle, gut and endothelium.

The primary mechanism is VEGFR2 activation — the phosphorylation of vascular endothelial growth factor receptor 2 leads downstream through PI3K/Akt/eNOS to new blood-vessel formation ^[10]. A second vascular axis is modulation of vasomotor tone through Src-Caveolin-1-eNOS — a mechanism that is partly resistant to L-NAME (an NOS inhibitor), suggesting BPC-157 drives nitric oxide production through a route separate from classical eNOS ^[10]. BPC-157 also upregulates the growth-hormone receptor in tendon fibroblasts, providing a tissue-selective repair-signaling mechanism.

The canonical result is the Achilles-tendon transection study: 10 μg/kg, 10 ng/kg or 10 pg/kg intraperitoneally in Wistar rats, once daily, improved healing across biomechanical load-to-failure, functional motor tests, histological collagen organization and macroscopic tendon integrity ^[2]. The dose-range spanning three orders of magnitude is unusual and is among the features most frequently discussed in the literature.

A 2025 first-in-human IV safety pilot administered 10 mg on day 1 and 20 mg on day 2 in 250 cc saline to two adults (a 58-year-old male and a 68-year-old female); no adverse events were observed and no changes in cardiac, hepatic, renal, thyroid or glucose biomarkers were detected ^[6]. This is a safety observation in a two-person pilot — not an efficacy signal, and not a basis for extrapolation to other doses, routes or populations.

BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review, restricting its use as a compounded formulation ingredient. It is not FDA-approved.

TB-500 — the cytoskeletal current

TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, MW 889.02 Da) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of native thymosin beta-4 (Tbeta4), the 43-amino-acid endogenous protein. The distinction between the fragment and the full-length protein is important: most of the large and well-replicated efficacy data in the TB-500 arm of KLOW refers to full-length Tbeta4, not the short fragment.

The fragment's mechanism, as established for the LKKTET motif, is G-actin sequestration — binding the globular, monomeric actin pool that cells use to extend their leading edge during migration. By sequestering G-actin, the fragment is linked to accelerated cell migration and wound re-epithelialization. Full-length Tbeta4 additionally activates integrin-linked kinase and mobilizes epicardial progenitor cells — activities that the short TB-500 fragment has not been shown to reproduce.

The quantitative benchmark from the thymosin beta-4 wound literature is the Malinda 1999 rat full-thickness wound model: +42% re-epithelialization at 4 days, +61% at 7 days, ≥11% increased wound contraction by day 7, increased collagen deposition and angiogenesis — and, critically, as little as 10 pg stimulated keratinocyte migration 2–3-fold in migration assays ^[1]. These are Tbeta4 numbers.

Thymosin beta-4 also upregulates VEGF in a HIF-1α-dependent manner ^[11], and a 2021 review covered its multiple potential roles in hair-follicle biology ^[8]. A 2026 Sports Medicine review concluded that unapproved peptides including TB-500 showed animal-model promise but scarce human safety data, with potential for serious harm and no regulatory approval ^[7].

On the WADA Prohibited List, thymosin beta-4 is a named S2 peptide hormone / growth factor, prohibited at all times. Because TB-500 is a thymosin beta-4 fragment, it implicates the prohibition; athletes and anyone subject to anti-doping rules should treat this arm — and therefore the full KLOW blend — as off-limits.

The four currents — what they share and where the evidence ends

Four nodes of the repair cascade. One vial. Each arm in its own signaling current — KPV's periwinkle anti-inflammatory channel, GHK-Cu's lavender-orchid matrix channel, BPC-157's cyan angiogenic channel, TB-500's misty-mauve cytoskeletal channel — contributing largely non-overlapping mechanisms to the tissue-repair process as theorized in the combination rationale.

What no study has measured is whether the four currents converge into a tide greater than their individual flows. The combination evidence belongs here — in this sentence — and has not been written yet. The honest record is: four plausible mechanisms, strong in some components (BPC-157 rodent literature, GHK-Cu human topical data, Tbeta4 wound-model numbers) and weaker in others (TB-500 fragment vs native protein, KPV human data limited to delivery systems), assembled into a blend that has never been tested in a controlled study against monotherapy or any subset. For KLOW effects reported by the research-use community and the safety cautions that follow from these mechanisms, follow the effects page.